Welcome to TCI’s New Website!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 61413-54-5 | Product Number: R0110
Rolipram
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 50MG |
€87.00
|
8 | ≥20 |
|
| 250MG |
€302.00
|
2 | 18 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | R0110 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__6H__2__1NO__3 = 275.35 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | -20°C |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 61413-54-5 |
| Reaxys Registry Number | 1588548 |
| PubChem Substance ID | 253659657 |
| Merck Index (14) | 8251 |
| MDL Number | MFCD00270906 |
Specifications
| Appearance | White to Orange to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 130.0 to 134.0 °C |
Properties (reference)
| Melting Point | 132 °C |
GHS
Related Laws:
| EC Number | 262-771-1 |
| RTECS# | UY5749237 |
Transport Information:
| HS Number | 2933790090 |
Application
Rolipram: A Selective PDE4 Inhibitor
Rolipram is a selective inhibitor of phosphodiesterases 4 (PDE4s) originally developed as an antidepressant agent in 1990s, but fell out of favor because of its undesirable gastrointestinal side effects. Nowadays, rolipram continues to be used in research as a PDE4 inhibitor. PDE4s are responsible for hydrolysis of the cyclic nucleotides cAMP [A2381] and cGMP to 5’-AMP [A0158] and 5’-GMP [G0338], particularly in nerve and immune cells. The inhibition of PDE4s by rolipram induces the elevation of intracellular cAMP concentration. Consequences rolipram-induced elevation of cAMP suppress expression of proinflammatory cytokines and other mediators of inflammation. Rolipram has been reported as a drug for the treatment of autoimmune diseases, Alzheimer's disease, cognitive enhancement, and respiratory diseases like asthma and COPD. Rolipram is a racemic compound, and (R)-rolipram [R0182] is more potent than (S)-rolipram [R0183] as a PDE4 inhibitor. (The product is for research purpose only.)
References
- The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
- Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory
- The antidepressant and antiinflammatory effects of rolipram in the central nervous system (a review)
- Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats
- Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
- Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease (a review)
PubMed Literature
Articles/Brochures
Documents
Safety Data Sheet (SDS) Search
Please select Language.
The requested SDS is not available.
• Please check that the Product Number you have entered is correct.
• If your information is correct and you are still not able to view the requested SDS, please Contact Us for more information.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number is entered